Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Ltd is an Australia-based biopharmaceutical company focused on melanocortin peptide therapies for genetic, metabolic, and dermatological disorders. Its portfolio is anchored by SCENESSE® (afamelanotide), a prescription therapy approved in multiple markets for patients with erythropoietic protoporphyria, alongside development programs in photomedicine and vitiligo.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2025–2026
Liiketoiminta
Osuus liikevaihdostaApproved treatment products sold for rare-disease indications, anchored by SCENESSE®.
Programs in development targeting photomedicine and dermatology indications.
Tuotteet
Raportoitu · osuus liikevaihdosta- Commercial Sales of Goods90,0 %
- Sales Under Special Access Reimbursement Programs10,0 %
Lähde: 20-F FY2026, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Clinuvel sells primarily to patients with erythropoietic protoporphyria through specialist physicians and treatment centers that administer SCENESSE®. Its development programs also target patients with dermatological and genetic disorders where melanocortin-based therapies may address unmet medical needs.
Patients receiving SCENESSE® to reduce phototoxicity and sun-related reactions.
Physicians and clinics that identify eligible patients, prescribe therapy, and manage administration.
Patients in adjacent dermatology and genetic disorder programs that may be served by future products.
Reimbursement decision-makers that influence access to specialty therapies.
Strategia
Clinuvel’s strategy centers on expanding the commercial reach of SCENESSE® while advancing melanocortin-based programs in photomedicine and vitiligo. The company is also aligning its corporate and capital-markets structure with the U.S., reflecting the importance of the American market to future development and commercialization.
The approved product is the core revenue-generating asset and anchors the business model.
Additional indications can broaden the addressable market beyond EPP.
The U.S. market is a major commercialization and capital-markets opportunity.
Maantiede
2026Clinuvel is headquartered in Melbourne, Australia, but its commercial footprint is international, with SCENESSE® approved in Europe, the United States, Canada, Israel, and Australia. The business is exposed to healthcare reimbursement, regulatory approvals, and specialist treatment access across these markets, while its Nasdaq listing adds a U.S. capital markets presence.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
Clinuvel’s business depends on a small number of specialty indications and on continued access to regulated healthcare markets, so adoption, reimbursement, and regulatory outcomes can materially affect growth. Development-stage programs add clinical and approval risk, while the company is also exposed to country-specific healthcare policy, treatment-center concentration, and competition from alternative rare-disease approaches.
- Concentration in SCENESSE®Vaikutus: KorkeaTodennäköisyys: Korkea
A large share of business depends on one approved therapy and its narrow indication.
Kohdistuu: Commercial revenue concentration
- Clinical development uncertaintyVaikutus: KorkeaTodennäköisyys: Kohtalainen
Photomedicine and vitiligo programs may not demonstrate efficacy or gain approval.
Kohdistuu: Pipeline programs
- Reimbursement and market accessVaikutus: KorkeaTodennäköisyys: Kohtalainen
Specialty therapies rely on payer coverage and specialist treatment access.
Kohdistuu - Regulatory and pharmacovigilanceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Approved medicines remain subject to ongoing safety, labeling, and compliance oversight.
Kohdistuu: Commercial markets
Kirjanpito
Harkinnanvaraiset erätSpecialty drug sales can be affected by shipment timing, patient treatment cycles, and market access.
Vaikutus: Quarterly comparability and revenue timing
Clinical programs in photomedicine and vitiligo may generate significant R&D expense and judgments over capitalization.
Vaikutus: Reported earnings and asset base
Pipeline assets and commercial intangibles require periodic recoverability assessments.
Vaikutus: Possible non-cash write-downs
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Crinetics Pharmaceuticals, Inc.
Pharmaceutical Preparations
Crinetics Pharmaceuticals is a U.S.-based biopharmaceutical company focused on endocrine diseases and endocrine-related tumors.
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
MediciNova, Inc
MNOV · Pharmaceutical Preparations
MedicNova Inc.
ProQR Therapeutics N.V.
PRQR · Pharmaceutical Preparations
Apellis Pharmaceuticals, Inc.
Pharmaceutical Preparations
Apellis Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company built around complement inhibition, with pegcetacoplan as its core molecule.
Clearside Biomedical, Inc.
CLSDQ · Pharmaceutical Preparations
Päivitetty: 28.9.2026